In PNAS this week: induced "BRCAness" phenotype in non-small cell lung cancer, chemoproteomic profiling approach, and more.
Three researchers have won this year's Nobel Prize in Medicine or Physiology for their work uncovering how cells react to changing oxygen levels.
In PNAS this week: cell division rates decline with age, different genetic lineages of chytrid fungus found, and more.
The company said it has seen progress in efforts to get FDA approval for its tissue and liquid biopsy tests as data continues to accumulate for pan-cancer utility.
Researchers found that 14 percent of individuals with metastatic breast cancer had risky mutations germline mutations, including patients who did not meet testing criteria.
NanoView will develop custom antibody-based assays on its ExoView platform to identify EVs containing biomarkers potentially linked to the neurological disorders.
The team will create a group called the Extracellular RNA Communication Consortium Stage 2 to develop new EV-based technology and treat diseases.
The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
Researchers analyzed RNA sequencing data gathered from induced pluripotent stem cells as they differentiated into heart muscle cells.
Thrive Earlier Detection is banking on targeted detection of frequent cancer mutations, coupled with protein markers, while competitors turn to genome-wide approaches.
In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.
Canadian regulators are beginning to share information from new drug studies, Undark reports.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.